-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

602.O2.3 602. Myeloid Oncogenesis: Basic: CRISPR Screens and Other New Approaches to Understanding Myeloid Neoplasia

Symposia: Myeloid Oncogenesis: Basic Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Acute Myeloid Malignancies, AML, Apoptosis, Assays, Translational Research, Drug development, Genomics, Bioinformatics, CML, Hematopoiesis, Chronic Myeloid Malignancies, Diseases, Immunology, Treatment Considerations, Computational biology, Myeloid Malignancies, Biological Processes, Molecular biology, Technology and Procedures, Gene editing, Profiling, Pathogenesis, Omics technologies
Monday, December 9, 2024: 4:30 PM-6:00 PM
Seaport Ballroom ABCD (Manchester Grand Hyatt San Diego)
Moderators:
Kentson Lam, MD, PhD, University of California, San Diego and Dang Hai Nguyen, PhD, University of Minnesota
Disclosures:
No relevant conflicts of interest to declare.
These studies use various functional genetics approach to identify novel vulnerabilities of AML cells.
4:30 PM

Ruka Shimura, MSc1*, Moe Tamura, PhD2*, Keita Yamamoto, MD, PhD2*, Kohei Iida, PhD2*, Shuhei Asada, MD, PhD3, Emi Sugimoto, PhD2*, E. Christine Pietsch, PhD4, Barbara A. Weir4*, Ramona Crescenzo, PhD5*, Glenn S. Cowley4*, Ricardo M. Attar, PhD6*, Ulrike Philippar, PhD7, Satoshi Yamasaki, PhD8*, Taisei Hirouchi, PhD9*, Kaoru Uchimaru, MD, PhD9*, Toshio Kitamura, MD, PhD10,11 and Susumu Goyama, MD, PhD2*

1Graduate School of Frontier Sciences, The University of Tokyo, Minato-Ku, Japan
2Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan
3The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
4Janssen Research and Development, Spring House, PA
5Janssen Research and Development, Beerse, Belgium
6Janssen Research & Development, Spring House, PA
7Janssen Research & Development, Beerse, Belgium
8Institute of Medical Science, University of Tokyo, Tokyo, Japan
9Laboratory of Tumor Cell Biology, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan
10Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
11Institute of Biomedical Research and Innovation, Foundation for Biomedical Research and Innovation at Kobe, Kobe, Japan

4:45 PM

Pu Zhang1*, Zhendong Cao1*, Xiangyu Pan1*, Yuqiao Liu2*, Cynthia Castro1*, Won Jun Kim1*, Takeshi Fujino3*, Jennifer Lewis1*, Jahan Rahman4*, Sanam Shahid, MD5, Jasmine S. Um3*, Erin R. Burns3*, Bing-Yi Chen3*, Winson Cai3*, Juliana Ortiz-Pacheco1*, Zhuoning Li1*, Mara Monetti1*, Anthony F. Daniyan, MD6*, Christopher R. Vakoc, MD, PhD7*, Omar Abdel-Wahab, MD8 and Junwei Shi, PhD9*

1Memorial Sloan Kettering Cancer Center, New York
2University of Pennsylvania, Philadelphia
3Memorial Sloan Kettering Cancer Center, New York, NY
4Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY
5Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
6Department of Medicine, Cell Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY
7Cold Springs Harbor Laboratory, Cold Spring Harbor, NY
8Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
9Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

5:00 PM

Dimitrios Papaioannou, MD1, Giovanni Gambi, PhD2*, Palaniraja Thandapani, PhD3*, Deedra Nicolet, MS4*, Ziyan Lin5*, Krzysztof Mrózek, MD, PhD4, Olha Ivashkiv2*, Maria Sirenko, PhD6, Bettina Nadorp, PhD7*, Ann-Kathrin Eisfeld, MD4,8, Aristotelis Tsirigos, PhD2,5* and Iannis Aifantis, PhD6

1Department of Medicine, Division of Hematology/Oncology, NYU Grossman School of Medicine, New York, NY, New York, NY
2Department of Pathology, New York University Grossman School of Medicine, New York, NY
3MD Anderson Cancer Center, Houston
4The Ohio State University Comprehensive Cancer Center, Columbus, OH
5Applied Bioinformatics Laboratories, New York University Grossman School of Medicine, New York, NY
6Department of Pathology, NYU Grossman School of Medicine, New York, NY
7NYU Grossman School of Medicine, Division of Precision Medicine, Department of Medicine, New York, NY
8Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH

5:15 PM

Pablo R Freire, PhD1*, Brandon Regalado2*, Elizabeth Ener3*, Jevon Cutler, PhD2, Christian Marinaccio, PhD2*, Vassilena Sharlandjieva4*, Thomas A Milne4 and Scott A Armstrong, MD, PhD2,5

1Department of Pediatric Oncology, Dana-Farber Cancer Institute, Jamaica Plain, MA
2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
3Stanford University, Palo Alto, CA
4Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
5Boston Children's Hospital, Boston

5:30 PM

Travis Fleming, BS1,2,3*, Richard A Voit, MD, PhD2,3,4,5*, Mateusz Antoszewski, PhD1,2,3*, Sander Lambo, PhD2,3,4*, Michael Gundry, MD, PhD2,3,4*, Riccardo Piussi2,3,4*, Sanjana Shah2,3,4, Lara Wahlster, MD, PhD2,3,4, Andrea Arruda6*, Volker Hovestadt, PhD2,3,4*, Mark D. Minden, MD, PhD6,7* and Vijay G. Sankaran, MD, PhD2,3,4

1Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, MA
2Division of Pediatric Oncology, Dana-Farber Cancer Institute / Harvard Medical School, Boston, MA
3Broad Institute of MIT and Harvard, Cambridge, MA
4Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA
5Department of Pediatrics, Division of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas, TX
6Princess Margaret Cancer Centre / University Health Network, Toronto, ON, Canada
7Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada

5:45 PM

Amog Urs, PhD1, Dimitrios Papaioannou, MD2, Rohan Kulkarni, PhD3*, Chinmayee Goda, PhD4*, Remi Buisson5*, Deedra Nicolet, MS6*, Lauren Woodward7*, Krzysztof Mrózek, MD, PhD6, Gregory K Behbehani, MD, PhD8, Sakari Kauppinen9*, Ann-Kathrin Eisfeld, MD6, Iannis Aifantis, PhD10, Guramrit Singh11*, Adrienne M. Dorrance, PhD12 and Ramiro Garzon, MD13*

1Huntsman Cancer Institute At the University of Utah, Salt Lake City, UT
2Perlmutter Cancer Center, Department of Medicine, Division of Hematology/Oncology, NYU Grossman School of Medicine, New York, NY, New York, NY
3Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT
4Huntsman Cancer Institute, Salt Lake City
5Department of Biological Chemistry, University of California Irvine, Irvine, CA
6The Ohio State University Comprehensive Cancer Center, Columbus, OH
7New York University School of Medicine, New York
8Division of Hematology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH
9Aalborg University, Copenhagen, DNK
10Department of Pathology, NYU Grossman School of Medicine, New York, NY
11The Ohio State University, Columbus
12Huntsman Cancer Institute at the University of Utah, Salt Lake City
13Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah Health, Salt Lake City, UT

*signifies non-member of ASH